Malignant gliomas remain largely incurable despite intensive efforts to develop novel therapies. Replicating oncolytic viruses have shown great promise, among them attenuated measles viruses of the Edmonston B strain (MV-Edm). However, host immune response and the infiltrative nature of gliomas limit their efficacy. We show that human blood outgrowth endothelial cells (BOECs), readily expandable from peripheral blood, are easily infected by MV-Edm and allow replication of MV-Edm while surviving long enough after infection to serve as vehicles for MV-Edm (BOEC/MV-Edm). After intravenous and peritumoral injection, BOEC/MV-Edm deliver the viruses selectively to irradiated orthotopic U87 gliomas in mice. At the tumor, MV-Edm produced by the BOECs infect glioma cells. Subsequent spread from tumor cell to tumor cell leads to focal infection and cytopathic effects that decrease tumor size and, in the case of peritumoral injection, prolong survival of mice. Since MV-Edm within BOECs are not readily neutralized and because BOEC/MVEdm search and destroy glioma cells, BOEC/MV-Edm constitute a promising novel approach for glioma therapy.
Introduction
Nearly all patients with malignant gliomas die from their disease and prognosis has improved only little over decades. The efficacy of locoregional therapies such as a surgical resection, irradiation, radioimmunotherapy and gene therapy is modest at best. One major reason is the limited delivery of the therapeutic moiety to the glioma cells. This is exemplified by the failure of gene therapy, which, when directly aimed against glioma cells, is hampered by low gene transfer efficacy requiring a complete bystander effect impossible to achieve. A second major reason for the failure of existing local therapies is the infiltrative growth of malignant glioma leading to the formation of glioma cell clusters isolated within normal brain tissue. These are inaccessible without risking destruction of normal brain tissue. Systemic therapy is also inefficient in glioma patients despite recent advances. This is in part due to the blood-brain barrier, which, although impaired, remains partially functional in malignant gliomas and hinders their systemic therapy by drugs, DNA or viruses.
Replicating oncolytic viruses are emerging as a promising modality for the treatment of malignant gliomas and other malignancies. They promise to overcome the problem of limited delivery of the therapeutic agent since, in principle, the successful infection of only a few tumor cells should suffice for subsequent spread to most tumor cells. A variety of replicating oncolytic viruses are being investigated. A recent addition to this arsenal is attenuated measles virus of the Edmonston B vaccine strain (MV-Edm; reviewed in Nakamura and Russell 1 and Fielding 2 ). MV-Edm infects cells by preferentially binding to CD46 3, 4 rather than to CD150, as wild-type MV does. The higher density of CD46 on malignant cells, including malignant gliomas, 5 compared to non-malignant cells contributes to the preferential killing of tumor cells by MV-Edm. 6 Once MV-Edm has infected tumor cells it spreads to noninfected tumor bystander cells by cell-to-cell contact. 7, 8 MV-Edminfected tumor cells form syncytia 9 induced by the F-protein of the virus, eventually leading to cell death that includes programmed cell death. 10 MV-Edm has been shown in animal models to have oncolytic activity against human lymphoma, 9 multiple myeloma, 11 ovarian cancer, 12, 13 malignant glioma, 5 fibrosarcoma 14 and against cutaneous T-cell lymphoma in patients. 15 As for other replicating oncolytic viruses, host immune response and cellular barriers limit infection by and intratumoral spread of MV-Edm, respectively. MV is readily neutralized by serum antibodies from humans immune to measles, which is true for most adults. Although cancer patients are usually immunocompromised and the brain may be an 'immune-privileged' site, an immune response against MV-Edm may still be mounted, limiting infection of gliomas by MV-Edm. As the spread of MV-Edm depends on tumor-cell-to-tumorcell contact, noninfectable cells such as most nonmalignant cells will impede the spread of MV-Edm. This problem is accentuated in malignant gliomas because of their propensity for infiltrative growth.
Various cellular vehicles can be envisioned to deliver therapeutic agents to experimental brain tumors. These include neural progenitors derived from the patient, from cadavers or fetuses, or generated from embryonic stem cells. However, clinical, logistical, immunological and ethical considerations will limit their use (reviewed in Jarmy et al. 16 ). In contrast, bone marrow-derived cells, known to target experimental tumors including gliomas, [17] [18] [19] are more easy to procure. Blood outgrowth endothelial cells (BOECs), in particular, are readily obtained from human peripheral blood. 20 They can be massively expanded ex vivo and lend themselves to genetic manipulation. BOECs are progenitor cells with a microvascular endothelial phenotype 20, 21 expressing VEGFR2, VEGFR1, vWF, CD31, VE-cadherin, a v b 3 , a v b 5 and CD105. They do not or only marginally express CD133, c-kit, CD45, CXCR4, ESL (E-selectin ligand), CD162, cutaneous lymphocyte-associated Ag, CD49d, CD11a and CD11b. The expression of CD34 varies. BOECs take up acetylated low-density lipoprotein and build vessel-like structures on Matrigel. BOECs have been shown to seek experimental tumors, invade them and incorporate into tumor structures. 21 However, when armed with the cytosine deaminase gene and administered intravenously (i.v.), they did not prolong the life of mice bearing disseminated metastases of Lewis lung carcinoma. 21 A major reason for this failure was the temporary and spatially limited bystander effect on tumor cells, the limitation being caused by suicide of the BOECs upon prodrug administration.
We reasoned that combining the tumor-seeking and protective ability of BOECs with the sustained and far reaching oncolytic 'lateral effect' of attenuated measles virus might control experimental brain tumors. We show in this study that MV-Edm within BOECs are protected against MV-neutralizing serum antibodies and are carried in mice through normal brain tissue to orthotopic malignant glioma cells, infect them, decrease tumor size and increase survival.
Results
BOECs express CD46 and can be infected by MV-Edm while being resistant to MV-Edm-mediated cell death
To employ BOECs as tumor-targeting cellular vehicles for MV-Edm, we first had to verify whether BOECs can be infected by MV-Edm. Expression of CD46, the preferred receptor for MV-Edm, on BOECs was strong and comparable with U87 glioma cells, A549 lung carcinoma cells and the myelomonocytic leukemia cell line K562, and was markedly stronger than on monocytes ( Figure 1a ).
We then determined whether MV-Edm infect and replicate within BOECs. Indeed, the virus titer (TCID 50 ) of lysates of BOECs infected with MV-Edm increased 139-fold as compared to the virus inoculum within 3 days after infection (Figure 1b) . Human monocytes, another potential cellular vehicle for MV, also supported MV replication, whereas replication in human lymphocytes was limited (Figure 1b) . Despite efficient replication, the majority of BOECs did not succumb to MV 3 days after infection (Figure 1c) , in contrast to monocytes. Thus, BOECs, but not monocytes or lymphocytes, support replication of MV for several days without dying.
While BOECs initially resisted MV-induced cell death, human cancer cell lines, such as A549 lung carcinoma and U87 glioma cells, were readily killed by MV-Edm (Figure 1d) .
Infection with MV-Edm may change homingassociated surface molecules of BOECs. However, no change in the expression of VEGFR2 (KDR), CXCR4, VE-Cadherin, a v b 5 , CD11a, CD11b, CD49d, CD162 and cutaneous lymphocyte-associated Ag was detected 1 and 24 h after infection (data not shown).
Taken together, BOECs could be infected by MV-Edm without being quickly killed or downregulating homingassociated surface molecules. This suggests that they are suitable cellular vehicles for MV-Edm.
BOECs do not carry loosely adsorbed MV-Edm-eGFP on their surface after infection with MV-Edm-eGFP
We investigated whether MV-Edm added to BOECs in vitro just adhere to the BOECs' surface and subsequently become released to infect surrounding cells. To this end, Vero indicator cells were incubated with cellfree washes of BOEC/MV-Edm-eGFP. While BOECs were clearly infected with MV-Edm-eGFP, as seen by the green fluorescence of BOECs (Figure 2 , left panel), no infectious MV-Edm-eGFP could be detached by washing and trypsinizing after infection as no Vero cells became infected ( Figure 2 , right panel).
MV-Edm spread from BOECs to neighboring U87 glioma cells and exert a strong bystander effect
It is crucial for any therapeutic vehicle to effectively release its payload to the target cells. As determined by fluorescence microscopy, MV-Edm-eGFP spread rapidly from single BOEC/MV-Edm cells to surrounding U87 cells (Figures 3Aa-c) and then to more distant U87 cells (Figures 3Ad-f ). The few GFP-positive foci of U87 cells that were not adjacent to the BOEC/MV-Edm may have originated from MV-Edm-eGFP released into the culture medium by dying tumor cells. The spread of MV-EdmeGFP induced multinuclear syncytia of U87 cells ( Figures  3Ag and h ) and caused their death ( Figure 3B ). Low numbers of BOEC/MV-Edm sufficed to cause a strong bystander effect on U87 glioma cells ( Figure 3B ). These data show that MV-Edm efficiently spread from BOECs to tumor cells and kill them.
MV-Edm protected within BOECs from measles antibodies infect bystander tumor cells in the presence of measles immune serum
Clinical application of MV-Edm as an oncolytic virus faces the potential hurdle of pre-existing measles antibodies in most patients. Indeed, infection of U87 by MV-Edm was almost completely abrogated by human MV immune serum (Figure 4Aa) , which rescued the viability of U87 cells (Figure 4Ac , upper panels). Of note, just 1% immune serum sufficed to prevent MV-Edm-induced cell death (Figure 4Ac ). In contrast, MV antibody-negative serum did not prevent infection ( Figure 4Ab ) and cell death (Figure 4Ac , lower panels) of U87 cells by MV-Edm.
We reasoned that BOECs should protect MV-Edm from neutralization by human measles antibodies. To simulate the situation that would occur in immune hosts immediately after i.v. injection of BOEC/MV-Edm, we first exposed BOEC/MV-Edm to human measles immune serum for a short period of time (30 min) before adding them to U87 cells. As shown in Figure 4B , 48 h later MV-Edm had spread to surrounding U87 cells and formed syncytia, even when BOEC/MV-Edm had been preincubated with measles immune serum at concentrations as high as 90% ( Figure 4B , right panel). In contrast, when MV-Edm was exposed to immune serum, the infectious capability of MV-Edm on tumor cells was neutralized ( Figure 4B , left panel).
Next we wanted to know whether the protection of MV-Edm provided by the BOECs would allow the spread of MV-Edm during continuous exposure to human measles immune serum. After a 30 min preincubation with measles immune serum, BOEC/MV-Edm were added to U87 glioma cells in the presence of 90% measles immune serum. Indeed, despite the continuous presence of measles antibodies, MV-Edm-eGFP spread from a single BOEC/MV-Edm-eGFP (Figure 4Cb , arrow) to surrounding U87 cells and to more distant tumor cells, eventually causing the formation of a syncytium ( Figure  4Cd ). This suggests that the spread of MV-Edm from We first confirmed that BOECs target orthotopic gliomas. Since irradiation has been shown to promote homing of hematopoietic progenitors toward gliomas, 19 cranial irradiation was employed prior to i.v. injection of BOECs. Because the autofluorescence of U87 gliomas complicates the interpretation of fluorescent signals, BOECs were labeled ex vivo with BrdU. Anti-BrdU staining showed i.v. injected BOECs within the gliomas but not in surrounding normal brain tissue (Figures 6Aa-c) .
Next, we determined whether BOEC/MV-Edm given i.v. prolong the life of mice with orthotopic U87 gliomas. After five i.v. injections of BOEC/MV-Edm (denoted by arrows in Figure 6B ), there was only a slight, albeit statistically significant, survival advantage ( Figure 6B , red line) compared to control mice treated with uninfected BOECs or PBS (green and black lines, respectively). Mice treated with cell-free MV-Edm i.v. (blue line) survived significantly longer than both the control and the BOEC/MV-Edm-treated groups.
Magnetic resonance imaging (MRI) images of fixed brains of mice that died on day 28 revealed significantly smaller tumors in mice treated with BOEC/MV-Edm when compared to nontreated mice ( Figure 6C ). When tumor volumes were calculated from the MRI images, the volume of gliomas treated with BOEC/MV-Edm was clearly smaller than that of untreated gliomas ( Figure 6C ).
Peritumorally injected BOEC/MV-Edm migrate to orthotopic U87 gliomas
Given the infiltrative nature of gliomas leading to small clusters of glioma cells that initially lack vessels, an efficient cellular vehicle has to search for glioma cells navigating through normal brain tissue. Since a robust infiltrative human glioma mouse model is lacking, we investigated cell migration by injecting BrdU-labeled BOEC/MV-Edm into normal brain tissue surrounding U87 gliomas. Two days after BOEC injection, BOECs were visualized by anti-BrdU staining. While the majority of BOECs remained at the injection site ( Figure  7Aa ), numerous BOECs migrated toward the tumor ( Figure 7Ab ) and accumulated there ( Figure 7Ac ). To determine the presence of measles virus in the glioma, adjacent sections were stained separately with antimeasles hemagglutinin antibody and anti-BrdU, thus avoiding the pitfalls of immunohistochemical double staining. BrdU-positive BOECs were seen at sites where MV were detected (compare the MV-containing cells in Figure 7Bc with the BOECs in Figure 7Bd ). This indicates that the peritumorally injected BOEC/MV-Edm carried MV-Edm to the tumor mass.
We then investigated whether BOECs target orthotopic gliomas in mice passively immunized against measles virus. Intraperitoneal injection of human measles antibodies generated levels of measles-specific immunoglobin G (IgG) antibodies in the blood known to prevent measles in humans (ELISA index greater than 1.1). Such preventive levels were found at 1 h, increased at 6 h and were still present 28 h after injection (data not shown). The presence of antibodies against measles virus did not preclude that many BOEC/MV-Edm injected peritumorally migrated into the tumor (Figures 7Ca-c) . Only very few BOEC/MV-Edm migrated into the normal brain tissue (Figures 7Ca-c) .
To address the specificity of homing of BOECs, we injected BrdU-labeled human fibroblasts peritumorally into glioma-bearing mice (Figure 7Da ). The fibroblasts did not migrate into the gliomas (Figure 7Db ) nor into the surrounding normal brain tissue ( Figure 7Dc ). Thus, the ability of BOECs to target gliomas is specific.
Peritumorally injected BOEC/MV-Edm significantly prolong survival of mice with orthotopic U87 gliomas by focal infection
Having shown the tumor searching capability of BOEC/ MV-Edm navigating through the brain, we wanted to clarify whether peritumorally applied BOEC/MV-Edm prolong survival of mice with orthotopic U87 gliomas. 
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Discussion
Inefficient delivery of therapeutic modalities and isolation of glioma cells due to infiltrative growth are major hurdles toward improving the poor prognosis of malignant gliomas. We show that replicating oncolytic The ease of BOEC generation as well as determinants of efficacy concerning their use in gene therapy of peripheral metastases has been established previously. 20, 21 MV-Edm infected and efficiently replicated within BOECs without killing them during the first few days after infection. This predisposes BOECs to be carriers for MV-Edm as compared to other blood-derived cells such as monocytes, which were rapidly killed by replicating MV-Edm, and lymphocytes, which did not allow MVEdm to replicate sufficiently. BOECs were resistant to MV-Edm-induced cell death despite the strong expression of CD46, known not only to function as the entry receptor for MV but also to determine the degree of cell death. 6 The multitude of antiapoptotic mechanisms operative in endothelial cells most likely accounts for this resistance. These mechanisms include VEGF-induced PI3K-mediated signaling, nuclear factor-kB activation and strong expression of Bcl-2, survivin and XIAP, and of antioxidative enzymes such as MnSOD, catalase and glutathione peroxidase (reviewed in Jarmy et al.
16
). Many cell types infected with MV-Edm are killed by complement-mediated lysis, which is facilitated by downregulation of CD46, an inhibitor of complementmediated lysis, after MV-Edm infection. 22 Of note, BOEC/MV-Edm were not killed when subjected to human measles immune serum containing complement. CD46 may not have been downregulated yet and MV proteins may not have appeared yet on the surface of infected BOECs during the time of transit to the tumor. Furthermore, the degree of downregulation of CD46 may be limited in BOECs. Further studies will elucidate the mechanisms involved.
Homing of BOEC/MV-Edm into gliomas also occurred when measles virus antibodies were present at levels sufficient to protect humans from measles. It remains to be shown whether BOEC/MV-Edm are susceptible to T cell-mediated destruction. The low number of T cells in cancer patients secondary to disease and previous chemotherapy may reduce this potential problem. T cells may also exert a beneficial effect by reacting against MV-Edm-infected tumor cells, thus enhancing the oncolytic effect of MV-Edm.
Specific and efficient homing of BOEC/MV-Edm to gliomas is crucial for their therapeutic efficacy. Intravenously injected BOECs homed into irradiated orthotopic U87 malignant gliomas, but did not sequester into normal brain tissue. More importantly, when BOEC/MV-Edm were injected peritumorally to simulate the situation in the patient, where BOEC/MV-Edm have to reach isolated glioma cells not yet connected to blood vessels, BOEC/ MV-Edm navigated through normal brain tissue to the glioma mass. Migration appeared to be directional, because far more BOEC/MV-Edm were seen within the glioma than in the normal brain tissue surrounding the injection site and since human fibroblasts injected in the same manner did not target gliomas. It is important to note that infection with MV-Edm did not preclude migration of peritumorally injected BOECs, even in mice immune against measles virus.
Cranial irradiation was employed assuming that it would increase migration of BOECs to gliomas as has been described for hematopoietic stem cells. However, we could not demonstrate increased infiltration of BOECs into irradiated tumor spheroids; 23 thus the role of irradiation in the homing of BOECs remains to be elucidated.
Once at the glioma cells, MV-Edm residing within the BOECs have to infect the glioma cells. This was indeed the case, despite the heterologous nature of BOECs and glioma cells. We have no evidence that infection of surrounding cells occurred by MV-Edm-eGFP that remained loosely adsorbed on the surface of BOECs following their infection with MV-Edm-eGFP ex vivo. However, it remains possible that some MV-Edm-eGFP strongly tethered to the BOECs surface may have contributed to the infection of tumor bystander cells.
After infection of glioma cells surrounding the BOEC/ MV-Edm, the virus spread to more distal glioma cells and killed them. In vitro, a few BOEC/MV-Edm sufficed to infect a far larger number of glioma cells and to kill most of them. In vivo, glioma cells were infected and killed by intratumorally injected BOEC/MV-Edm leading to a significant survival benefit of glioma-bearing mice indistinguishable from those receiving intratumorally injected MV-Edm. Of note, despite the presence of MV-neutralizing serum antibodies in vitro, MV-Edm spread from BOECs to surrounding and then to more distant glioma cells inducing syncytia. This shows that U87 glioma cells can be controlled by BOEC/MV-Edm in the face of natural MV-neutralizing activity. As a corollary, spread by tumor-cell-to-tumor-cell contact, as Figure 5 Intratumorally injected BOEC/MV-Edm significantly prolong the life of mice with orthotopic U87 gliomas. 5 Â 10 5 U87 glioma cells were stereotactically injected into the right striatum of 10-to 12-week-old male Rag2 À/À cgc À/À mice. Ten days later, mice were randomized into three groups (n ¼ 5 for each group). The treatment groups received two intratumoral injections (denoted by arrows) spaced 1 day apart of either 2 Â 10 5 BOEC/MV-Edm or 3 Â 10 5 PFU MV-Edm, while the control group received PBS. Survival was determined and plotted for Kaplan-Meier survival analysis and analyzed by log-rank test. Compared to PBS (black line), survival of both BOEC/MV-Edm (red line) and MV-Edm (blue line) was prolonged (P ¼ 0.0088 and 0.0018, respectively). BOECs, blood outgrowth endothelial cells; MV-Edm, measles viruses of the Edmonston B strain; PBS, phosphate-buffered saline.
Oncolytic measles virus and BOEC J Wei et al has been described for MV-Edm in other tumors, 7, 8 appears to be the relevant route MV-Edm can spread in U87 gliomas.
We show that i.v. injected BOEC/MV-Edm home specifically to orthotopic U87 gliomas and that BOEC/ MV-Edm decrease the size of the tumors, as detected by MRI. However, because the responses were partial (with some tumors continuing to grow into the brain stem, as in Figure 6Ce ), the survival benefit was minute. In contrast, i.v. injected cell-free MV prolonged survival more pronounced than i.v. injected BOEC/MV-Edm. It is known that some i.v. injected BOECs are sequestered in the lung and the spleen. 21 Sequestration of i.v. injected MV-Edm may be less, which could explain their increased efficacy. In addition, the blood-brain barrier is less permeable for large cells such as BOECs than for viruses with their smaller size. This may also have led to increased extravasation of MV-Edm into the cerebrospinal fluid and thus to increased infection of tumors abutting the ventricle.
I.v. injection of MV-Edm will not be feasible in most patients, given their immunity against measles. BOEC/ MV-Edm are not affected by measles antibodies; however, they show limited efficacy against gliomas when given i.v. Thus, intracranial injection of BOEC/MV-Edm is an obvious route to ensure high-level and consistent delivery. We injected BOEC/MV-Edm peritumorally to mimic the clinical situation, where BOECs would have to Figure 6Aa ), intrathecal injection of BOEC/MV-Edm may be the most efficient route of delivery.
While tumor size decreased and survival was prolonged upon administration of BOEC/MV-Edm, no cures were achieved since responses were partial, as shown by MRI. Intratumoral heterogeneity of response was reflected on the cellular level. After peritumoral injection, BOEC/MV-Edm infiltrated and infected large parts of the tumors. At the time of death, however, the distribution of syncytia and MV-Edm-infected cells was focal. There are several explanations for this finding. First, proliferation of uninfected tumor cells must have outpaced the spread of MV, in line with recent findings in experimental ovarian carcinoma. 24 It remains to be determined whether attenuation of the spread of MVEdm contributes to this. Second, the presence of foci of persistent MV-Edm infection without cytopathic effect suggests resistance of tumor cells to MV-Edm-induced cell death. Finally, the migratory function of BOECV/ MV-Edm within the tumor must have subsided, most likely because MV-Edm finally overcame the resistance of BOECs to early cell death. Elucidating the mechanisms of intratumoral virus spread and of MV-Edm-induced cell death, and modulating them, such as by arming MVEdm with additional tumor cytotoxic effectors, 11, 25, 26 will address the challenge of increasing the efficacy of BOEC/ MV-Edm for therapy of gliomas and other tumors.
Several oncolytic viruses in diverse cellular vehicles have been successful in preclinical studies. These encompass herpes simplex virus-1 in human teratocarcinoma cells, 27 retrovirus in outgrowth endothelial cells, 28 retrovirus on antigen-specifc T cells 29 and modified vaccinia virus in cytokine-induced killer cells. 30 Their relative merit for glioma therapy has yet to be defined. The nonintegrating MV do not carry the risk of insertional mutagenesis, unlike retroviruses. Not all the positive features of BOECs are shared by the other cellular vehicles that have been used to carry oncolytic viruses to experimental tumors. Tumor antigen-specific T cells, for example, are complex to generate, 29 a feature they share with neural progenitors that target experimental brain tumors, 31 and may lack the ability to navigate through normal brain tissue. The latter may also apply to cytokine-induced killer cells. 30 In conclusion, BOEC/MV-Edm warrant to be included in future studies of cellular vehicles carrying oncolytic viruses for the therapy of gliomas.
Materials and methods
Cell culture
Tissue culture media and supplements were obtained from Life Technologies (Eggenstein, Germany) unless stated otherwise. BOECs were isolated from human adult peripheral blood, propagated as described 16 and cultured in ECBM-2 medium (PromoCell, Heidelberg, Germany) supplemented with SupplementPack (PromoCell) and 10% fetal calf serum (FCS) (Biochrom, Berlin, Germany). Human mononuclear cells were isolated from peripheral blood cells and separated into monocytes and lymphocytes by adherence to plastic. Monocytes were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FCS and 15% human serum. Lymphocytes were cultivated in RPMI supplemented with 10% FCS, 50 mM 2-mercaptoethanol, 1 mM pyruvate and 30 U ml À1 interleukin-2 (Pepro Tech, Rocky Hill, NJ, USA). U87, K-562 cells and Vero cells were Oncolytic measles virus and BOEC J Wei et al obtained from ATCC (Manassas, VA, USA) and A549 was obtained from the German Collection of Microorganisms and Cell Cultures (Braunschweig, Germany). K-562 cells were maintained in RPMI and all other tumor cell lines were grown in DMEM. Cell culture media for cell lines were supplemented with 10% FCS, 2 mM glutamine, 2 mM nonessential amino acids, 100 U ml À1 penicillin and 100 mg ml À1 streptomycin.
Virus production and infection
The construction of MV-Edm-eGFP has been described elsewhere. 32 MV-Edm and MV-Edm-eGFP were propagated by Vero cells with a MOI of 0.02 in 2 ml OptiMEM (Life Technologies) at 37 1C for 3 h. The medium was changed to DMEM supplemented with 5% FCS and cells were incubated at 37 1C for 1 day before being transferred to 32 1C for another day. Cells were harvested Lymphocytes were infected in suspension for 3 h at 37 1C. After centrifugation the medium was replaced with the appropriate culture medium described above.
MV-Edm replication
BOECs and monocytes were seeded at 2 Â 10 5 cells per well (six-well plate) and infected the following day with MV-Edm at a MOI of 2 for 3 h. Lymphocytes were infected in suspension at a MOI of 2 for 3 h and than seeded at 2 Â 10 5 cells per well. At 24, 48 and 72 h after infection, the cells were scraped into 1 ml OptiMEM (Invitrogen, Karlsruhe, Germany) and the cell-associated viruses were released by two freeze-thaw cycles. Viral titers were determined as TCID 50 on Vero cells. 
Determination of viability in vitro
Prior to determination of viability, cell culture plates were ultraviolet irradiated to inactivate MV. Viability of cells was determined by MTT (3-(4,5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide) assay as described. 33 To determine viability by crystal violet staining, cells were incubated in 0.75% crystal violet ethanol solution at room temperature for 15 min, washed, dried and photographed.
Bystander effect assays
BOECs infected with MV-Edm were added to U87 glioma cells seeded at 2 Â 10 3 cells per well in DMEM 
MV neutralization assays
Serum was obtained from a healthy donor with immunity against measles as defined by high levels of measlesspecific IgG antibodies using an appropriate ELISA. Nonimmune serum (as determined by ELISA) was obtained from nonimmune humans. Sera were centrifuged at 14 000 r.p.m. for 10 min at 4 1C before use. 5 Â 10 4 PFU MV-Edm-eGFP were incubated with MV immune serum or with nonimmune serum at concentrations of 0.0, 1.0 and 10.0% in OptiMEM at 37 1C for 30 min. MV-Edm-eGFP at a MOI of 5 in 50 ml OptiMEM were added to 2 Â 10 3 U87 glioma cells per well growing in collagen I-coated 96-well plates 2 h after infection, the infectious medium was removed, cells were washed once with PBS and then cultivated in supplemented DMEM. Cell viability was determined by crystal violet staining as described above. The spread of MV-Edm-eGFP and syncytia formation was monitored by fluorescence microscopy.
MV protection by BOECs in vitro
To investigate protection by BOECs of MV-Edm against the neutralizing effect of measles immune serum, BOECs were infected with MV-Edm-eGFP at a MOI of 2 in OptiMEM for 3 h at 37 1C and then maintained in supplemented ECBM-2 medium. Twenty-four hours after infection, BOEC/MV-Edm-eGFP were harvested and MV-Edm-eGFP were incubated in OptiMEM containing 0.0, 10.0, 50.0 and 90.0% measles immune serum at 37 1C for 30 min. Hundred BOEC/MV-Edm-eGFP or 1 Â 10 4 MV-Edm-eGFP per well were then added to U87 glioma cells seeded at 2 Â 10 3 cells per well on collagen Icoated 96-well plates. Two hours after the addition of BOEC/MV-Edm-eGFP or MV-Edm-eGFP, U87 cells were washed once with PBS followed by incubation in supplemented DMEM.
To investigate the spread of MV-Edm from BOECs to U87 cells in the presence of measles immune serum, BOEC/MV-Edm were preincubated with 90% measles immune serum as above and then cocultivated with U87 cells in the presence of 90% measles immune serum in supplemented DMEM for 4 days.
Fluorescence-activated cell sorting analysis
Cells were incubated with phycoerythrin-conjugated monoclonal antibodies against CD11a, CD11b, CD49d, CD162 and CXCR4 (all from BD Biosciences Pharmingen, Heidelberg, Germany), with fluorescein isothiocyanateconjugated monoclonal antibodies against cutaneous lymphocyte-associated Ag (BD Biosciences Pharmingen), VE-cadherin (Bender MedSystems, Vienna, Austria) and with unconjugated antibodies against VEGFR2 (Sigma, Munich, Germany), CD46 and integrin a v b 5 (both from BD Biosciences Pharmingen) followed by fluorescein isothiocyanate-conjugated goat anti-mouse secondary antibody (DAKO, Hamburg, Germany). All incubations were performed for 30 min at 4 1C. Isotype-matched antibodies (BD Biosciences Pharmingen) served as controls. Analyses were performed using a FACScan flow cytometer and CellQuest software (BD Biosciences).
Immunohistochemistry
Organs were perfused with PBS and 4% paraformaldehyde, further fixed for 2 h in 4% paraformaldehyde, cryoprotected in 20% sucrose/PBS (Roth, Karlsruhe, Germany), embedded in optimal cutting temperature compound (Sakura Finetek, Zoeterwoude, The Netherlands) at À801C and serially cut into 7-mm-thick sections. Slides were microwaved in 0.01 M citrate acid solution (pH 6.0) twice for 5 min and incubated with 1% bovine serum albumin (Serva, Heidelberg, Germany). To detect BrdU-incorporating cells, slides were incubated with anti-BrdU monoclonal antibody (1:20; Roche, Mannheim, Germany) followed by alkaline phosphatase-conjugated anti-mouse IgG (Roche) and visualized by Fast Red (DAKO). To detect MV-Edm-infected cells, slides were blocked with MOM mouse Ig blocking reagent (Vector Laboratories Inc. Burlingame, CA, USA) and then incubated with mouse anti-measles hemagglutinin monoclonal antibody (Chemicon, Temecula, CA, USA) followed by alkaline phosphatase-conjugated anti-mouse IgG (DAKO) and visualized by Fast Red (DAKO). Hematoxylin was used for subsequent counterstaining.
Animal studies Intracranial xenografting of human glioma cells. 5 Â 10 5 U87 glioma cells in 5 ml DMEM were stereotactically injected into the right striatum of Rag2 À/À cgc À/À mice. Mice were anesthetized with xylazine and ketamine during the procedure. All animal work was carried out in accordance with state guidelines for animal care and use.
In vivo homing. Fourteen days after injection of U87 cells, when tumors had formed, the mice received 6 Gy of cranial g-irradiation ( 137 Cs; Gammacell 40, Nordion, Kanata, Canada). Three days later, 1 Â 10 5 BOECs pulsed with BrdU at a concentration of 10 mM for 5 days were injected into the tail vein once (n ¼ 3). Tumor-bearing mice not receiving BOECs were used as controls (n ¼ 3). One day later, brains were procured, fixed in 4% paraformaldehyde (PFA), cryosectioned and examined by immunohistochemistry for BrdU-incorporating cells as described above.
Transfer of antibodies against measles virus into mice. Serum was isolated from a healthy donor with immunity against measles as determined by high levels of measles-specific IgG antibodies (index 7.247) using an ELISA (Enzygnost Anti-MeaslesVirus/IgG, DADE Behring GmbH, Marburg, Germany). The serum was inactivated at 56 1C for 30 min, centrifuged at 14 000 r.p.m. for 10 min and proven to completely neutralize MV-Edm in vitro (data not shown).
To determine the duration of protection against measles, 500, 750 and 1000 ml of measles immune serum was injected intraperitoneally into two mice for each dose and blood was drawn at 1, 6, 18 and 28 h. The levels of measles-specific human IgG antibodies were determined by ELISA (Enzygnost Anti-Measles-Virus/IgG, DADE Behring GmbH), previously validated to perform correctly after dilution in mouse serum.
Intracranial migration of BOECs and fibroblasts. Mice with striatal U87 gliomas received 6 Gy of cranial g-irradiation. Two days later, mice were immunized with Oncolytic measles virus and BOEC J Wei et al 500 ml human measles immune serum injected intraperitoneally or were not immunized. Eighteen hours later, 2 Â 10 5 BOECs pulsed with BrdU and infected with MV-Edm were injected peritumorally (n ¼ 4 for the immunized and nonimmunized group). A nonimmunized control group with irradiated gliomas received human foreskin fibroblasts pulsed with BrdU (n ¼ 4). Two days after BOEC injection, mouse brains were procured, fixed in 4% PFA, cryosectioned and examined by immunohistochemistry for BrdU incorporation and for the presence of MV-Edm.
In vivo survival studies. To determine the efficacy of intratumoral injections, mice with established striatal gliomas generated by the growth of 5 Â 10 5 U87 cells for 10 days received daily intratumoral injections given for 2 days. Tumors of the treatment groups were injected with 3 Â 10 5 PFU MV-Edm in 5 ml OptiMEM (n ¼ 5) or with 2 Â 10 5 BOEC/MV-Edm harvested 1 h after infection with MV-Edm at a MOI of 1.5 (n ¼ 5). Tumors of the control group (n ¼ 5) were injected with 5 ml PBS.
To investigate the effects of intravenous injections, mice with established striatal U87 gliomas generated by the growth of 5 Â 10 5 human U87 glioma cells for 4 days were subjected to 6 Gy of cranial g-irradiation. Two days later, mice were randomized into three groups to receive daily tail vein injections for 5 days. The treatment groups were injected with 4 Â 10 5 PFU MV-Edm in 200 ml PBS (n ¼ 7) or with 2 Â 10 5 BOEC/MV-Edm harvested 1 h after infection with MV-Edm at an MOI of 2 (n ¼ 6). The control group was injected with 200 ml PBS (n ¼ 8).
To determine the efficacy of peritumoral injections, mice with striatal U87 gliomas established by the growth of 5 Â 10 5 human U87 glioma cells for 4 days received 6 Gy of cranial g-irradiation. Two days later, daily peritumoral injections of BOEC/MV-Edm were given for 3 days. Each day, injections were applied to a different peritumoral location, that is approximately 1 mm superior, 0.5 mm lateral and 0.5 mm posterior to the glioma. The treatment groups received 3 Â 10 5 PFU MV-Edm in 5 ml OptiMEM (n ¼ 7) or 2 Â 10 5 BOEC/MV-Edm harvested 1 h after infection with MV-Edm at an MOI of 1.5 (n ¼ 7). Control groups received 2 Â 10 5 BOECs (n ¼ 7) or 5 ml PBS (n ¼ 6).
Animals were followed until they were moribund, at which time they were killed.
MRI scanning procedure and image analysis
MRI was performed with formalin-fixed mouse brains on a 4.7-T BRUKER Biospec scanner (Bruker Biospin MRI, Ettlingen, Germany) by generating high-resolution T 2 -weighted spin echo images. Twenty sagittal and 20 axial slices were acquired covering the entire brain (slice thickness: 0.5 mm). Images were analyzed using ParaVision software (Bruker Biospin MRI). Borderlines of tumors were delineated using a tracking function, the volume of tumor tissue was calculated for each slice and then added from all slices to obtain the total tumor volume.
Statistical analysis
Survival data were analyzed by Kaplan-Meier estimator analysis and compared using the log-rank test. Po0.05 were considered significant.
